
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6517731/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reducing Inappropriate Polypharmacy. JAMA Internal Medicine, 2015, 175, 827.	2.6	1,054
2	Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Research and Treatment, 2010, 123, 627-635.	1.1	785
3	Therapeutic drug monitoring of antimicrobials. British Journal of Clinical Pharmacology, 2012, 73, 27-36.	1.1	263
4	Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2092-2103.e6.	2.4	237
5	Assessment of Nonischemic Myocardial Fibrosis. Journal of the American College of Cardiology, 2010, 56, 89-97.	1.2	219
6	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	0.6	174
7	A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 17-35.	1.8	136
8	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 2020, 180, 895-914.e27.	13.5	127
9	Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2011, 4, 693-702.	1.3	122
10	The development and evaluation of an oncological palliative care deprescribing guideline: the †OncPal deprescribing guideline'. Supportive Care in Cancer, 2015, 23, 71-78.	1.0	112
11	Minimizing Inappropriate Medications in Older Populations: A 10-step Conceptual Framework. American Journal of Medicine, 2012, 125, 529-537.e4.	0.6	104
12	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-?. Cardiovascular Research, 2005, 65, 694-701.	1.8	102
13	Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiology and Drug Safety, 2010, 19, 1019-1024.	0.9	101
14	Resveratrol – pills to replace a healthy diet?. British Journal of Clinical Pharmacology, 2011, 72, 27-38.	1.1	100
15	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clinical Biochemist Reviews, 2010, 31, 21-4.	3.3	98
16	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	0.6	97
17	Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evidence-Based Medicine, 2013, 18, 121-124.	0.6	95
18	Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. Cannabis and Cannabinoid Research, 2018, 3, 21-34.	1.5	93

#	Article	IF	CITATIONS
19	The role of the GP in follow-up cancer care: a systematic literature review. Journal of Cancer Survivorship, 2016, 10, 990-1011.	1.5	85
20	Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. British Journal of Clinical Pharmacology, 2018, 84, 2468-2476.	1.1	85
21	Polypharmacy among inpatients aged 70 years or older in Australia. Medical Journal of Australia, 2015, 202, 373-377.	0.8	83
22	Using routine inpatient data to identify patients at risk of hospital readmission. BMC Health Services Research, 2009, 9, 96.	0.9	78
23	Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovascular Research, 2007, 76, 280-291.	1.8	72
24	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Medicine Journal, 2011, 41, 537-543.	0.5	69
25	Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseases. International Journal of General Medicine, 2016, 9, 137.	0.8	69
26	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. British Journal of Clinical Pharmacology, 2016, 81, 210-222.	1.1	69
27	"LONG COVIDâ€â€"A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacology Research and Perspectives, 2022, 10, e00911.	1.1	69
28	Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. BMC Cancer, 2014, 14, 517.	1.1	66
29	Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. Supportive Care in Cancer, 2014, 22, 1113-1119.	1.0	64
30	Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open, 2015, 5, e007451-e007451.	0.8	59
31	IN VITRO INHIBITORY EFFECTS OF ATORVASTATIN ON CARDIAC FIBROBLASTS: IMPLICATIONS FOR VENTRICULAR REMODELLING. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 697-701.	0.9	58
32	Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. British Journal of Clinical Pharmacology, 2015, 80, 1281-1288.	1.1	58
33	Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis and Cannabinoid Research, 2018, 3, 94-107.	1.5	58
34	Drugâ€Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	2.3	58
35	Incretinâ€based therapies – review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal, 2011, 41, 299-307.	0.5	57
36	Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2860-H2869.	1.5	54

#	Article	IF	CITATIONS
37	Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. British Journal of Clinical Pharmacology, 2001, 51, 627-630.	1.1	49
38	Aiming to be NEAT: safely improving and sustaining access to emergency care in a tertiary referral hospital. Australian Health Review, 2014, 38, 564.	0.5	49
39	Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class. Drug Safety, 2003, 26, 13-21.	1.4	48
40	Fibrosis as a Therapeutic Target Post-Myocardial Infarction. Current Pharmaceutical Design, 2005, 11, 477-487.	0.9	46
41	Quality of drug interaction alerts in prescribing and dispensing software. Medical Journal of Australia, 2009, 190, 251-254.	0.8	44
42	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. Journal of Neuro-Oncology, 2015, 122, 263-271.	1.4	44
43	Drug-associated pulmonary arterial hypertension. Clinical Toxicology, 2018, 56, 801-809.	0.8	43
44	Individualised medicine: why we need Bayesian dosing. Internal Medicine Journal, 2017, 47, 593-600.	0.5	40
45	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Annals of Oncology, 2020, 31, 236-245.	0.6	39
46	Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterology, 2014, 14, 97.	0.8	37
47	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clinical Pharmacokinetics, 2016, 55, 807-812.	1.6	36
48	Optimising lowâ€dose methotrexate for rheumatoid arthritis—A review. British Journal of Clinical Pharmacology, 2019, 85, 2228-2234.	1.1	36
49	Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development. Therapeutic Drug Monitoring, 2010, 32, 615-623.	1.0	35
50	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. Journal of Medical Radiation Sciences, 2015, 62, 92-98.	0.8	35
51	Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. British Journal of Clinical Pharmacology, 2016, 81, 199-209.	1.1	35
52	Defining and classifying terminology for medication harm: a call for consensus. European Journal of Clinical Pharmacology, 2019, 75, 137-145.	0.8	35
53	Therapeutic drug monitoring to adjust dosing in morbid obesity – a new use for an old methodology. British Journal of Clinical Pharmacology, 2012, 73, 685-690.	1.1	33
54	Medicationâ€Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention. Hepatology Communications, 2019, 3, 620-631.	2.0	33

#	Article	IF	CITATIONS
55	Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Research and Treatment, 2012, 136, 323-330.	1.1	32
56	When less is more – efficacy with less toxicity at the ED50. British Journal of Clinical Pharmacology, 2017, 83, 1365-1368.	1.1	32
57	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). BMC Palliative Care, 2019, 18, 110.	0.8	31
58	Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?. Clinical Pharmacokinetics, 2018, 57, 539-545.	1.6	30
59	Clinical trials of medicinal cannabis for appetiteâ€related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation. Internal Medicine Journal, 2016, 46, 1269-1275.	0.5	29
60	Pharmacokineticâ€Guided Dosing of New Oral Cancer Agents. Journal of Clinical Pharmacology, 2017, 57, S78-S98.	1.0	28
61	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 142, 16-25.	2.0	28
62	Smoking and drug interactions. Australian Prescriber, 2013, 36, 102-104.	0.5	28
63	Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Medical Oncology, 2014, 31, 881.	1.2	27
64	Usefulness of At Rest and Exercise Hemodynamics to Detect Subclinical Myocardial Disease in Type 2 Diabetes Mellitus. American Journal of Cardiology, 2011, 107, 615-621.	0.7	26
65	Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. European Journal of Cancer, 2021, 157, 428-440.	1.3	26
66	Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men. European Journal of Clinical Nutrition, 2013, 67, 377-384.	1.3	25
67	Prevalence of medication discrepancies in patients with cirrhosis: a pilot study. BMC Gastroenterology, 2016, 16, 114.	0.8	25
68	A Validated Method for the Detection of 32 Bath Salts in Oral Fluid. Journal of Analytical Toxicology, 2017, 41, 659-669.	1.7	25
69	Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World Journal of Gastroenterology, 2017, 23, 7321-7331.	1.4	25
70	The interacting physiology of COVIDâ€19 and the reninâ€angiotensinâ€aldosterone system: Key agents for treatment. Pharmacology Research and Perspectives, 2022, 10, e00917.	1.1	25
71	Longitudinal Patterns of Breast Cancer Screening: Mammography, Clinical, and Breast Self-Examinations in a Rural and Urban Setting. Women's Health Issues, 2014, 24, e139-e146.	0.9	24
72	Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors. Supportive Care in Cancer, 2017, 25, 1597-1605.	1.0	24

#	Article	IF	CITATIONS
73	Statins and clinical outcomes in heart failure. Clinical Science, 2007, 113, 119-127.	1.8	23
74	Optimising care of patients with chronic disease: patientâ€oriented education may improve disease knowledge and selfâ€management. Internal Medicine Journal, 2017, 47, 952-955.	0.5	23
75	Altered Sympathetic and Parasympathetic Activity in Lung Transplantation Patients at Rest and Following Autonomic Perturbation. Chest, 2002, 122, 1192-1199.	0.4	22
76	ROLE OF VALSARTAN AND OTHER ANGIOTENSIN RECEPTOR BLOCKING AGENTS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASE. Pharmacological Research, 2002, 46, 203-212.	3.1	22
77	Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling. British Journal of Clinical Pharmacology, 2018, 84, 2483-2487.	1.1	22
78	Precision dosing of targeted anticancer drugs—challenges in the real world. Translational Cancer Research, 2017, 6, S1500-S1511.	0.4	22
79	eGFR — use beyond the evidence. Medical Journal of Australia, 2009, 190, 197-199.	0.8	21
80	Reduced End-Systolic Pressure-Volume Ratio Response to Exercise. Circulation: Cardiovascular Imaging, 2010, 3, 443-449.	1.3	21
81	The Effect of a High-Fat Meal on Postprandial Arterial Stiffness in Men with Obesity and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4455-4459.	1.8	21
82	Impact of dose-rate on the low-dose hyper-radiosensitivity and induced radioresistance (HRS/IRR) response. International Journal of Radiation Biology, 2013, 89, 813-822.	1.0	21
83	Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer Chemotherapy and Pharmacology, 2016, 78, 209-216.	1.1	21
84	Health-related quality of life among Indigenous Australians diagnosed with cancer. Quality of Life Research, 2016, 25, 1999-2008.	1.5	21
85	Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia. Internal Medicine Journal, 2017, 47, 429-435.	0.5	21
86	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials, 2020, 21, 611.	0.7	21
87	Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priorityâ€driven, Indigenousâ€led research program. Medical Journal of Australia, 2011, 194, 530-531.	0.8	20
88	Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2014, 15, 776-786.	0.5	20
89	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVIDâ€19 and response to treatment. Pharmacology Research and Perspectives, 2022, 10, e00922.	1.1	20
90	Pill testing at music festivals: can we do more harm?. Internal Medicine Journal, 2016, 46, 1249-1251.	0.5	19

#	Article	IF	CITATIONS
91	A Validated Method for the Detection of Synthetic Cannabinoids in Oral Fluid. Journal of Analytical Toxicology, 2019, 43, 10-17.	1.7	19
92	Target Concentration Intervention in Oncology. Therapeutic Drug Monitoring, 2012, 34, 257-265.	1.0	18
93	The Effects of Tai Chi in Centrally Obese Adults with Depression Symptoms. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-8.	0.5	18
94	Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacology Research and Perspectives, 2021, 9, e00757.	1.1	18
95	Factors Associated With Cancer-Specific and Overall Survival Among Indigenous and Non-Indigenous Gynecologic Cancer Patients in Queensland, Australia. International Journal of Gynecological Cancer, 2015, 25, 542-547.	1.2	17
96	Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia. European Journal of Cancer Care, 2018, 27, e12714.	0.7	17
97	Spotlight Commentary: Modelâ€informed precision dosing must demonstrate improved patient outcomes. British Journal of Clinical Pharmacology, 2019, 85, 2238-2240.	1.1	17
98	Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety, 2020, 29, 1325-1330.	0.9	17
99	Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. British Journal of Clinical Pharmacology, 2022, 88, 64-74.	1.1	17
100	Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer. Cancer Causes and Control, 2009, 20, 355-360.	0.8	16
101	Medicinal cannabis in Australia: the missing links. Medical Journal of Australia, 2016, 204, 371-373.	0.8	16
102	Health professional's perspectives of the barriers and enablers to cancer care for Indigenous Australians. European Journal of Cancer Care, 2016, 25, 254-261.	0.7	16
103	Valproate in Adjuvant Glioblastoma Treatment. Journal of Clinical Oncology, 2016, 34, 3105-3107.	0.8	14
104	Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998–2004): does being Indigenous make a difference?. International Journal of Public Health, 2016, 61, 435-442.	1.0	14
105	Parasitic pharmacology: A plausible mechanism of action for cannabidiol. British Journal of Clinical Pharmacology, 2020, 86, 189-191.	1.1	14
106	Drug repurposing in the era of <scp>COVID</scp> â€19: a call for leadership and government investment. Medical Journal of Australia, 2020, 212, 450.	0.8	14
107	Ensuring access to safe, effective, and affordable cannabisâ€based medicines. British Journal of Clinical Pharmacology, 2020, 86, 630-634.	1.1	14
108	Acidosis in the hospital setting: is metformin a common precipitant?. Internal Medicine Journal, 2010, 40, 342-346.	0.5	13

#	Article	IF	CITATIONS
109	The future of thiopurine pharmacogenomics. Pharmacogenomics, 2012, 13, 1549-1552.	0.6	13
110	Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 165-177.	0.8	13
111	Achieving the World Health Organization's vision for clinical pharmacology. British Journal of Clinical Pharmacology, 2016, 81, 223-227.	1.1	13
112	Cytochrome P450 drug interactions: are they clinically relevant?. Australian Prescriber, 2001, 24, 10-12.	0.5	13
113	Medicines optimisation in older people: Taking age and sex into account. Maturitas, 2016, 93, 114-120.	1.0	12
114	Ezetimibe: Use, costs, and adverse events in Australia. Cardiovascular Therapeutics, 2017, 35, 40-46.	1.1	12
115	Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials, 2017, 18, 339.	0.7	12
116	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. Clinical Therapeutics, 2018, 40, 1442-1447.	1.1	12
117	The rationale of dose–response curves in selecting cancer drug dosing. British Journal of Clinical Pharmacology, 2019, 85, 2198-2204.	1.1	12
118	Khatâ€associated hepatitis. Medical Journal of Australia, 2013, 199, 498-499.	0.8	11
119	Addressing unconscious bias for female clinical academics. Internal Medicine Journal, 2016, 46, 391-393.	0.5	11
120	Modelâ€based analysis on systemic availability of coâ€administered cannabinoids after controlled vaporised administration. Internal Medicine Journal, 2020, 50, 846-853.	0.5	11
121	Clinical trials with cannabis medicines—guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience. Trials, 2020, 21, 932.	0.7	11
122	Scanning for Safety. CIN - Computers Informatics Nursing, 2011, 29, 157-164.	0.3	11
123	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. Cancer Chemotherapy and Pharmacology, 2018, 82, 887-898.	1.1	10
124	Exploring Positive Survivorship Experiences of Indigenous Australian Cancer Patients. International Journal of Environmental Research and Public Health, 2018, 15, 135.	1.2	10
125	Effectiveness of patientâ€oriented education and medication management intervention in people with decompensated cirrhosis. Internal Medicine Journal, 2020, 50, 1142-1146.	0.5	10
126	Overcoming barriers to implementing precision dosing with 5â€fluorouracil and capecitabine. British Journal of Clinical Pharmacology, 2021, 87, 317-325.	1.1	10

#	Article	IF	CITATIONS
127	Role of Statins in Diabetes Complications. Current Diabetes Reviews, 2009, 5, 165-170.	0.6	9
128	Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. Internal Medicine Journal, 2016, 46, 826-833.	0.5	9
129	Identification of Australian Aboriginal and Torres Strait Islander Cancer Patients in the Primary Health Care Setting. Frontiers in Public Health, 2017, 5, 199.	1.3	9
130	Pharmacovigilance and expedited drug approvals. Australian Prescriber, 2018, 41, 50-53.	0.5	9
131	Community-identified recommendations to enhance cancer survivorship for Aboriginal and Torres Strait Islander people. Australian Journal of Primary Health, 2018, 24, 233.	0.4	9
132	Unmet supportive care needs among people with cancer: A crossâ€cultural comparison between Indigenous and Nonâ€Indigenous Australians. European Journal of Cancer Care, 2019, 28, e13080.	0.7	9
133	Vancomycin therapeutic drug monitoring in paediatrics. Journal of Paediatrics and Child Health, 2020, 56, 563-570.	0.4	9
134	Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population. Pharmacy (Basel, Switzerland), 2020, 8, 16.	0.6	9
135	Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians. International Journal of Integrated Care, 2020, 20, 10.	0.1	9
136	A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. British Journal of Cancer, 2022, 127, 126-136.	2.9	9
137	Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service. Clinical Medicine, 2010, 10, 540-543.	0.8	8
138	Surrogate endâ€points in clinical practice: are we providing worse care?. Internal Medicine Journal, 2010, 40, 395-398.	0.5	8
139	Effects of a Drug Minimization Guide on Prescribing Intentions in Elderly Persons with Polypharmacy. Drugs and Aging, 2012, 29, 659-667.	1.3	8
140	A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. British Journal of Clinical Pharmacology, 2014, 78, 274-281.	1.1	8
141	Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. Cancer Biology and Therapy, 2017, 18, 917-926.	1.5	8
142	"l'm a Survivor― Cancer Nursing, 2020, 43, 105-114.	0.7	8
143	Vancomycin: Audit of American guidelineâ€based intermittent dose administration with focus on overweight patients. British Journal of Clinical Pharmacology, 2020, 86, 958-965.	1.1	8
144	A pharmacological framework for integrating treating the host, drug repurposing and the damage response framework in COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 875-885.	1.1	8

#	Article	IF	CITATIONS
145	The hazards of rapid approval of new drugs. Australian Prescriber, 2016, 39, 2-3.	0.5	8
146	Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience. British Journal of Clinical Pharmacology, 2022, 88, 3101-3113.	1.1	8
147	Effect of Atorvastatin on Cardiac Remodelling and Mortality in Rats Following Hyperglycemia and Myocardial Infarction. International Journal of Cardiology, 2010, 143, 353-360.	0.8	7
148	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2011, 37, 90-92.	1.1	7
149	Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. Biochemical and Biophysical Research Communications, 2014, 444, 332-337.	1.0	7
150	Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting. Drugs in R and D, 2018, 18, 41-44.	1.1	7
151	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. British Journal of Clinical Pharmacology, 2019, 85, 2218-2227.	1.1	7
152	Patterns of primary health care service use of Indigenous Australians diagnosed with cancer. Supportive Care in Cancer, 2020, 28, 317-327.	1.0	7
153	Buying time: Drug repurposing to treat the host in COVIDâ€19H. Pharmacology Research and Perspectives, 2020, 8, e00620.	1.1	7
154	Editorial: Reporting adverse drug events to the Therapeutic Goods Administration. Australian Prescriber, 2021, 44, 2-3.	0.5	7
155	Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study. Pain and Therapy, 2022, 11, 171-189.	1.5	7
156	Drug Development. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 506-510.	0.9	6
157	<scp>BMI</scp> But Not Stage or Etiology of Nonalcoholic Liver Disease Affects the Diagnostic Utility of Carbohydrateâ€Deficient Transferrin. Alcoholism: Clinical and Experimental Research, 2013, 37, 1771-1778.	1.4	6
158	Rural–urban disparities in stage of breast cancer at diagnosis in <scp>A</scp> ustralian women. Australian Journal of Rural Health, 2016, 24, 326-332.	0.7	6
159	Safety and efficacy of statins. Lancet, The, 2017, 389, 1098.	6.3	6
160	Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians. Medical Journal of Australia, 2018, 208, 107-109.	0.8	6
161	Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients. European Journal of Clinical Pharmacology, 2019, 75, 1645-1657.	0.8	6
162	Precision medicineâ€based drug treatment individualization in oncology. British Journal of Clinical Pharmacology, 2021, 87, 223-226.	1.1	6

#	Article	IF	CITATIONS
163	Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1188, 123075.	1.2	6
164	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab <i>in Utero</i> : A Prospective Cohort Study in 107 Children. Journal of Crohn's and Colitis, 2022, 16, 1835-1844.	0.6	6
165	<scp>M</scp> ortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. Internal Medicine Journal, 2014, 44, 621-624.	0.5	5
166	Adding the â€~medicines' back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 2015, 80, 929-931.	1.1	5
167	Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?. Journal of Neuro-Oncology, 2015, 124, 1-3.	1.4	5
168	Clinical Consequences of a Miscalibrated Digoxin Immunoassay. Therapeutic Drug Monitoring, 2015, 37, 104-109.	1.0	5
169	The Impact of Model-Misspecification on Model Based Personalised Dosing. AAPS Journal, 2016, 18, 1244-1253.	2.2	5
170	Care and concern with cannabinoids used therapeutically. British Journal of Clinical Pharmacology, 2018, 84, 2455-2457.	1.1	5
171	<scp>NSW</scp> Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes. Internal Medicine Journal, 2022, 52, 228-237.	0.5	5
172	How reliable is eGFR when calculating drug dosage in acute medical admissions?. Internal Medicine Journal, 2011, 41, 327-331.	0.5	4
173	Enabling the success of academic health science centres in Australia: where is the leadership?. Medical Journal of Australia, 2014, 201, 636-638.	0.8	4
174	How â€~Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. Clinical Pharmacokinetics, 2016, 55, 1171-1177.	1.6	4
175	Obesity and COVID-19: renin–angiotensin as a mediator of morbidity and mortality. British Journal of Nutrition, 2022, 127, 1439-1440.	1.2	4
176	New medicines — urgent need to assess outcomes in special groups. Medical Journal of Australia, 2012, 196, 433-433.	0.8	3
177	Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care. Medical Journal of Australia, 2012, 196, 237-239.	0.8	3
178	Policy change to improve pathology turnaround time and reduce costs – possible to do both?. Biochemia Medica, 2013, 23, 296-302.	1.2	3
179	Clinical research in synthetic cannabinoids ―do we need a national approach?. Medical Journal of Australia, 2014, 201, 317-319.	0.8	3
180	New imaging techniques for more effective treatment in glioblastoma. Internal Medicine Journal, 2014, 44, 5-6.	0.5	3

#	Article	IF	CITATIONS
181	Improving ambulatory patient-centred practice with a patient teaching associate programme. Internal Medicine Journal, 2015, 45, 883-884.	0.5	3
182	Lipid and other management to improve arterial disease and survival in end stage renal disease. Expert Opinion on Pharmacotherapy, 2017, 18, 343-349.	0.9	3
183	Clinical benefits of evolocumab appear less than hoped. Lancet, The, 2018, 391, 933-934.	6.3	3
184	Weightâ€based tacrolimus trough concentrations post liver transplant. Internal Medicine Journal, 2019, 49, 79-83.	0.5	3
185	DRUG REPURPOSING—Overcoming the translational hurdles to clinical use. Pharmacology Research and Perspectives, 2019, 7, e00548.	1.1	3
186	Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins. Therapeutic Drug Monitoring, 2020, 42, 98-101.	1.0	3
187	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	1.6	3
188	Aboriginal and Torres Strait Islander patients' cancer care pathways in Queensland: Insights from health professionals. Health Promotion Journal of Australia, 2022, 33, 701-710.	0.6	3
189	Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient. New Zealand Medical Journal, 2003, 116, U542.	0.5	3
190	Guidelines or external regulation?. Internal Medicine Journal, 2009, 39, 789-791.	0.5	2
191	Old bugs new populations: an unusual presentation of pericarditis. Internal Medicine Journal, 2009, 39, 850-851.	0.5	2
192	From an evolutionary perspective, all †̃new' antimicrobial targets are old: time to think outside the box. British Journal of Clinical Pharmacology, 2015, 79, 165-167.	1.1	2
193	Offâ€label use of tumour necrosis factorâ€alpha inhibitors and anakinra at an Australian tertiary hospital. Internal Medicine Journal, 2016, 46, 1386-1391.	0.5	2
194	Predicting drug interactions in addiction treatment. Internal Medicine Journal, 2017, 47, 872-878.	0.5	2
195	Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. Journal of Pain and Palliative Care Pharmacotherapy, 2018, 32, 116-123.	0.5	2
196	Optimal cancer drug dosing in adolescents: new issues and the old unaddressed ones. Internal Medicine Journal, 2018, 48, 1023-1027.	0.5	2
197	Intensive lipidâ€lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Medical Journal of Australia, 2019, 211, 284.	0.8	2
198	Did our pharmacological strategy for COVIDâ€19 fail?. Pharmacology Research and Perspectives, 2021, 9, e00866.	1.1	2

#	Article	IF	CITATIONS
199	The HEART FAILURE Journal Club: a review of publications on heart failure in American Heart Journal. European Journal of Heart Failure, 2001, 3, 125-137.	2.9	1
200	Novel Drug Treatments for Hypertension. , 2007, , 1049-1060.		1
201	Statins and congestive heart failure. Current Atherosclerosis Reports, 2008, 10, 369-376.	2.0	1
202	Whither therapeutic drug monitoring?. Internal Medicine Journal, 2010, 40, 671-672.	0.5	1
203	Treatment for pulmonary hypertension in Australia: too far too fast?. Internal Medicine Journal, 2011, 41, 217-219.	0.5	1
204	Challenges of an ageing and dispersed population for delivering cancer services in Australia: more than just doctors needed. Internal Medicine Journal, 2012, 42, 349-351.	0.5	1
205	A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma. Current Pharmaceutical Analysis, 2017, 14, .	0.3	1
206	The challenge of discharge: combining medication reconciliation and discharge planning. Medical Journal of Australia, 2017, 206, 20-21.	0.8	1
207	Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study. Journal of Traditional Chinese Medical Sciences, 2018, 5, 100-109.	0.1	1
208	Letter to the Editor: Automated adverse drug reaction detection. Australian Prescriber, 2018, 41, 138.	0.5	1
209	Cannabinoid use in practice in Australasia—Better guidance and new drug information systems will be essential for prescribers. British Journal of Clinical Pharmacology, 2019, 85, 1664-1665.	1.1	1
210	Development of an UHPLC-MS/MS method for remifentanil quantification in a small plasma volume. Journal of Liquid Chromatography and Related Technologies, 2019, 42, 521-527.	0.5	1
211	Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology. British Journal of Clinical Pharmacology, 2020, 86, 1674-1677.	1.1	1
212	Effect of pharmaceutical regulatory policy on health impact. British Journal of Clinical Pharmacology, 2020, 86, 2335-2337.	1.1	1
213	College conferences: time for meritâ€based selection of speakers and educators?. Internal Medicine Journal, 2020, 50, 393-395.	0.5	1
214	Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology, 2021, , 1.	0.8	1
215	The Development of a Rapid, Simple and Sensitive LC-MS/MS Method, to Guide Clinical Dosing, for the Analysis of 5-Fluorouracil in Human Plasma. Current Pharmaceutical Analysis, 2017, 13, .	0.3	1
216	Editorial: The challenge of costly drugs. Australian Prescriber, 2016, 39, 72-4.	0.5	1

#	Article	IF	CITATIONS
217	On strongly unimodal third-order SISO linear systems with applications to pharmacokinetics. IFAC-PapersOnLine, 2020, 53, 4654-4661.	0.5	1
218	Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. Pharmaceuticals, 2021, 14, 1207.	1.7	1
219	Patientâ€oriented medication education intervention has longâ€ŧerm benefits for people with decompensated cirrhosis. Hepatology Communications, 2022, 6, 3281-3282.	2.0	1
220	Doctors and the pharmaceutical industry: time for a national policy?. Medical Journal of Australia, 2009, 191, 189-190.	0.8	0
221	Rapidly Progressive Severe Amiodarone-Induced Hypothyroidism in an Elderly Female. Journal of Pharmacy Practice and Research, 2009, 39, 140-141.	0.5	0
222	Drug Use Evaluation Services in Australia and New Zealand: a Neglected Area of Research?. Journal of Pharmacy Practice and Research, 2010, 40, 15-18.	0.5	0
223	ORIGINAL ARTICLE: Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 368-374.	0.9	0
224	Pharmacogenomics and Warfarin Therapy. , 2012, , 161-173.		0
225	Issues of Pharmacogenomics in Monitoring Warfarin Therapy. , 2016, , 261-277.		0
226	Medicinal cannabis in Australia: the missing links. Medical Journal of Australia, 2016, 205, 425-425.	0.8	0
227	Trading Lower HbA 1c for Increased Adverse Events. Journal of the American College of Cardiology, 2016, 68, 1372-1373.	1.2	0
228	Care with overseas purchased drugs: devil is in the detail. Internal Medicine Journal, 2016, 46, 1005-1006.	0.5	0
229	Introduction. Internal Medicine Journal, 2017, 47, 157-158.	0.5	0
230	Comment on a paper by Dupoiron etÂal. "A phase <scp>III</scp> randomized controlled study on the efficacy and improved bowel function of prolongedâ€release (<scp>PR</scp>) oxycodoneâ€raloxone (up) Tj ETC	QqQ40 0 rg	:BTD/Overlock
231	Selected state of the art research in internal medicine, 2017. Internal Medicine Journal, 2018, 48, 619-623.	0.5	0
232	Reply. Hepatology Communications, 2019, 3, 1283-1284.	2.0	0
233	Clinically Optimal Versus "Target―Doses in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 1425.	1.2	0
234	Are general practitioners getting the information they need from hospitals and specialists to provide quality cancer care for Indigenous Australians?. Internal Medicine Journal, 2020, 50, 38-47.	0.5	0

#	Article	IF	CITATIONS
235	Science and art of anticancer drug dosing: nine steps to personalised therapy. Internal Medicine Journal, 2020, 50, 992-996.	0.5	0
236	Andrew Lawrence, Editorâ€in hief 2018–2020. Pharmacology Research and Perspectives, 2020, 8, e00702.	1.1	0
237	Easier patient access to medical cannabis carries risks as well as benefits. Journal of Psychopharmacology, 2021, 35, 1435-1436.	2.0	0
238	<i>Pharmacology Research & amp; Perspectives</i> calls for pharmacology education papers. Pharmacology Research and Perspectives, 2021, 9, e00772.	1.1	0
239	Letter: The challenge of costly drugs. Australian Prescriber, 2016, 39, 149-149.	0.5	0
240	Defining the trials nursesâ \in ^{IM} role in operationalising a medicinal cannabis clinical trial. Collegian, 2021,	0.6	0
241	Critical insights to COVIDâ€19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology. Pharmacology Research and Perspectives, 2022, 10, e00918.	1.1	0
242	Melanoma: An immunotherapyÂjourney from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89.	0.2	0